The microbial effect of inhaled steroids in severe COPD patients with associated bronchiectasis The aim of the study is to investigate whether inhaled steroids along with other types of inhaler, that open the airways, can affect the amount and type of bacteria in the airways. This will be assessed over 1 year in patients with GOLD Stage D COPD and a co-diagnosis of bronchiectasis. Image Chief Investigator (UK): Dr Gourab Choudhury Number and location of participating sites (by region/ country): 3 UK Sites EudraCT number: 2022-000524-38 ISRCTN number: 15449782 Funder: Glaxo SmithKline Start and End date of grant award: 01 September 2021 to 29 February 2024 Start and End date of recruitment: May 2022 to January 2023 Current status: In set up UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document. Document TEMPESTAS GDRP STATEMENT (429.78 KB / PDF) UK Sponsor: University of Edinburgh & NHS Lothian ACCORD CI: Dr Gourab Choudhury, Royal Infirmary of Edinburgh, Little France, Edinburgh, EH16 4TJ email: Gourab.Choudhury@nhslothian.scot.nhs.uk Trial Management Team: Lorna Dewar – tempestas.trial@ed.ac.uk Research Nurse: Amy McLaren – amy.mclaren@nhslothian.scot.nhs.uk ECTU Involvement: Trial Management (UK only) (UKCRC) This article was published on 2024-09-24
